Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nanjing Vazyme Biotech Co (SHSE:688105) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Nanjing Vazyme Biotech Co Forward PE Ratio Related Terms
Nanjing Vazyme Biotech Co Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanjing Vazyme Biotech Co Forward PE Ratio Chart
Nanjing Vazyme Biotech Co Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
42.91
50.64
Nanjing Vazyme Biotech Co Quarterly Data
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
2026-06
Forward PE Ratio
42.91
56.02
104.19
58.22
50.64
54.68
65.64
SHSE:688105 vs VRTX, REGN, MRNA: Forward PE Ratio Comparison
For the Biotechnology subindustry, Nanjing Vazyme Biotech Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanjing Vazyme Biotech Co Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanjing Vazyme Biotech Co's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Nanjing Vazyme Biotech Co's Forward PE Ratio falls into.
Nanjing Vazyme Biotech Co Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Nanjing Vazyme Biotech Co (SHSE:688105) has a Forward PE Ratio of 58.91 as of Sep. 12, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Nanjing Vazyme Biotech Co and its competitors. According to the industry distribution chart, Nanjing Vazyme Biotech Co ranks #316 out of 386 companies in the Biotechnology industry, placing it in the top 81.9%.
Is Nanjing Vazyme Biotech Co's Forward PE Ratio too high?
Nanjing Vazyme Biotech Co's current Forward PE Ratio is 58.91. The Biotechnology industry median Forward PE Ratio is 20.40. Nanjing Vazyme Biotech Co's value of 58.91 is 188.8% above this industry median. Based on the distribution chart, Nanjing Vazyme Biotech Co ranks #316 out of 386 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nanjing Vazyme Biotech Co has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nanjing Vazyme Biotech Co's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanjing Vazyme Biotech Co ranks #316 out of 386 companies for Forward PE Ratio. This places Nanjing Vazyme Biotech Co in the lower half of its industry. The industry median Forward PE Ratio is 20.40. Nanjing Vazyme Biotech Co's value of 58.91 is 188.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 20.40, based on 386 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanjing Vazyme Biotech Co's current Forward PE Ratio of 58.91 is 188.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Nanjing Vazyme Biotech Co and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 20.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanjing Vazyme Biotech Co's current Forward PE Ratio is 58.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Vazyme Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Nanjing Vazyme Biotech Co (SHSE:688105) is currently considered Fairly Valued. The stock's GF Value™ is ¥21.53, compared to a current price of ¥19.50 — trading 9.4% below its estimated fair value. The current Forward PE Ratio is 58.91 and 188.8% above the Biotechnology industry median of 20.40. Nanjing Vazyme Biotech Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Nanjing Vazyme Biotech Co (SHSE:688105), the current Forward PE Ratio is 58.91 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanjing Vazyme Biotech Co (SHSE:688105) Overvalued in 2026?
Based on GuruFocus' analysis, Nanjing Vazyme Biotech Co stock appears to be undervalued.
The current stock price of ¥19.50 is trading 9.4% below its estimated GF Value™ of ¥21.53.
GuruFocus considers Nanjing Vazyme Biotech Co to be Fairly Valued.
Key valuation signals for SHSE:688105:
Forward PE Ratio: 58.91
GF Value™: ¥21.53 vs. price of ¥19.50 (9.4% below fair value)
Industry Position: 188.8% above the Biotechnology median (#316 of 386)
No single metric tells the full story. See the SHSE:688105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AddressKechuang Road, Floor 1-6, East Section, Building C1-2, Hongfeng Science and Technology Park, Jiangsu, Economic and Technological Development Zone, Nanjing, CHN, 210000
Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.
69GF Score
Get the complete analysis for SHSE:688105
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688105 has been successfully added to your 
